Good morning, everyone, and thank you so much for joining us. I want to start by briefly framing where Recursion is today and its journey and evolution. Over the past decade, Recursion has built ...

High-interest debt has a bad reputation — and rightfully so. Debt that charges high rates is the most expensive for borrowers to carry. And the longer you leave it unpaid, the quicker the costs grow, ...

On Wednesday, the Federal Open Market Committee (FOMC) declined to lower the federal funds rate. The target rate has remained at a range of 3.50% to 3.75% since December 2025. Adjustments to the fed ...

The conflict in the Middle East has continued into a second week and there are already major fears about the impact that soaring energy prices could have on people in the UK. In particular, rising ...

Evan Coleman is an Updates Editor on the Credit Cards and Travel Rewards team at Forbes Advisor, showcasing his interest in personal finance and love of travel. He has written for a variety of local ...

Adam Palasciano is a writer over three years of experience writing about personal finance, investing, student loans, and more, for outlets like GOBankingRates, FinanceBuzz, The Penny Hoarder, and Wall ...

Libby Sweeney is a former credit cards editor for Forbes Advisor. Her previous experience writing and editing content for readers to better understand includes both the world of sports and data ...

You’re more likely to find rates below 5% when you have a higher credit score Written By Written by Staff Senior Editor, Buy Side Miranda Marquit is a staff senior personal finance editor for Buy Side ...

Marcus’ CDs come with a guarantee that lets you earn the highest rate offered within 10 days of opening an account — not all financial institutions offer this kind of assurance. CDs are available in a ...

Arielle O’Shea leads the investing and taxes team at NerdWallet. She has covered personal finance and investing for nearly 20 years, and was a senior writer and spokesperson at NerdWallet before ...

Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...